Nevrox Overview
- Status
- Private
- Latest Deal Type
- Accelerator/Inc
- Investors
- 1
Nevrox General Information
Description
Developer of a neuroprotective small molecule drug intended for the treatment of Huntington disease (HD) and Amyotrophic Lateral Sclerosis (ALS). The company targets neurodegenerative disorders, enabling healthcare professionals to avoid characteristic misfolded proteins that aggregate and induce neuronal toxicity and death.
Contact Information
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- Rehov Ilan Ramon 2
- Nes Ziona 7403635
- Israel
Nevrox Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Accelerator/Incubator | Completed | Startup |
Nevrox Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Niva Segev Amzaleg | Chief Scientific Officer | ||
| Brent Stockwell Ph.D | Founder & Advisor |
Nevrox Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| FutuRx | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |